NTLA | Intellia Therapeutics Inc
Category: Biotechnology company
Quick infos Headquarters: Cambridge, Massachusetts, United States Trade prices Volume: Market Cap: 3.76B Prev closed: 13.36 Open: 13.87 High: 13.91 Low: 13.37 52 week low: 9.18 52 week high: 19 Dividends: No Dividends Next ER: May 5, 2022 Before Market Opens
About the Company Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and colleagues at University of California. The company has partnerships with Novartis and Regeneron.
Earnings History Date EPS / Forecast Revenue / Forecast August 4, 2022 May 5, 2022 -1.96 / -1.1311.25M / 8.7MBeat! February 24, 2022 -1.09 / -0.94912.85M / 8.26MBeat! November 4, 2021 -0.97 / -0.84717.2M / 8.66MAugust 5, 2021 -1.01 / -0.63426.55M / 12.21Mview more
Historical Data Date Price Open High Low Vol Change ER May 5, 2022 50.03 52.22 54.80
48.73
1.56M -10.18% May 4, 2022 55.70 51.85 56.73
49.38
1.61M 7.57% May 3, 2022 51.78 51.58 53.82
50.37
746.90K 0.33% May 2, 2022 51.61 48.00 51.83
47.08
1.20M 5.26% Apr 29, 2022 49.03 49.69 52.57
48.90
864.71K -2.51% Apr 28, 2022 50.29 50.41 51.84
47.02
1.08M 1.93% Apr 27, 2022 49.34 49.62 51.34
48.07
892.76K -1.02% Apr 26, 2022 49.85 52.79 54.12
49.75
898.98K -6.98% Apr 25, 2022 53.59 50.35 54.00
50.35
984.88K 5.78% Apr 22, 2022 50.66 50.93 52.89
50.20
781.96K 0.30% view more
NASDAQ - Nasdaq Stock Market
More profiles and info about the company Founded:2014 Employees:104 News
How Much Of Intellia Therapeutics, Inc. (NASDAQ:NTLA) Do Institutions Own? finance.yahoo.com Dec 22, 2020 11:06 am
Nobel Prize for Gene-Editing Innovators Boosts Crispr Therapeutics and Other Stocks barrons.com Dec 22, 2020 10:04 am
New Results on Blood Disorder Treatments Are Coming. Watch These Stocks. barrons.com Dec 22, 2020 8:00 am
Intellia Therapeutics Announces Second Quarter 2020 Financial Results finance.yahoo.com Dec 22, 2020 7:30 am
Analysts Have Lowered Expectations For Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its Latest Results finance.yahoo.com Dec 22, 2020 5:57 am
Genetics Stocks Ablaze: Editas, Crispr, Intellia Rocket; Uniqure Dives investors.com Dec 21, 2020 4:24 pm
Intellia Therapeutics Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment of AAT Deficiency finance.yahoo.com Dec 12, 2020 9:00 am
Gene-Editing Stocks Skyrocket in $1.6 Billion Boom After Data finance.yahoo.com Dec 9, 2020 11:06 am
Intellia Therapeutics Presents New Preclinical Data Supporting Its CRISPR/Cas9-Engineered TCR-T Cell Treatment for Acute Myeloid Leukemia at the 62nd ASH Annual Meeting finance.yahoo.com Dec 5, 2020 10:00 am Intellia Therapeutics on go with early-stage study of NTLA-2001 in rare metabolic disorder seekingalpha.com Oct 19, 2020 11:15 pm Intellia initiated at Overweight by Wells Fargo; major opportunities in pipeline seekingalpha.com Oct 15, 2020 1:50 am Intellia Therapeutics teed up by red-hot Ark Research seekingalpha.com Oct 12, 2020 9:23 pm
Goldman Sachs: These 3 Stocks Are Poised to Surge by at Least 50% finance.yahoo.com Sep 22, 2020 9:43 am
We're Not Worried About Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn finance.yahoo.com Aug 11, 2020 11:10 am
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock finance.yahoo.com Dec 1, 2020 9:30 pm
Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments finance.yahoo.com Nov 11, 2020 7:30 am
Intellia Therapeutics Announces Third Quarter 2020 Financial Results finance.yahoo.com Nov 5, 2020 7:30 am
Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2020 Earnings and Company Updates finance.yahoo.com Oct 29, 2020 7:30 am
Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR) finance.yahoo.com Oct 19, 2020 7:30 am CRISPR gene editing discoverers share Nobel Prize seekingalpha.com Oct 7, 2020 6:38 pm This company doesn't provide a dividend.
Key Persons CEO : Nessan Bermingham, PhD General Counsel : José Rivera Talk about Intellia Therapeutics Inc below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
Consensus
If you want to help pay for server cost or for improving this tool. You can send it via Paypal .
Buy on Amazon Graham's philosophy of "value investing" has made The Intelligent Investor the stock market bible ever since its original publication in 1949.
The best book on investing ever written.
